Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,096 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER).
Sattar N, Murray HM, McConnachie A, Blauw GJ, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Murphy MB, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG, Shepherd J; PROSPER Study Group. Sattar N, et al. Among authors: jukema jw. Circulation. 2007 Feb 27;115(8):981-9. doi: 10.1161/CIRCULATIONAHA.106.643114. Epub 2007 Feb 5. Circulation. 2007. PMID: 17283264 Clinical Trial.
Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS).
Jukema JW, Bruschke AV, van Boven AJ, Reiber JH, Bal ET, Zwinderman AH, Jansen H, Boerma GJ, van Rappard FM, Lie KI, et al. Jukema JW, et al. Circulation. 1995 May 15;91(10):2528-40. doi: 10.1161/01.cir.91.10.2528. Circulation. 1995. PMID: 7743614 Clinical Trial.
The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk.
Shepherd J, Blauw GJ, Murphy MB, Cobbe SM, Bollen EL, Buckley BM, Ford I, Jukema JW, Hyland M, Gaw A, Lagaay AM, Perry IJ, Macfarlane PW, Meinders AE, Sweeney BJ, Packard CJ, Westendorp RG, Twomey C, Stott DJ. Shepherd J, et al. Among authors: jukema jw. Am J Cardiol. 1999 Nov 15;84(10):1192-7. doi: 10.1016/s0002-9149(99)00533-0. Am J Cardiol. 1999. PMID: 10569329 Clinical Trial.
A Prospective Study of Pravastatin in the Elderly at Risk (PROSPER): Screening Experience and Baseline Characteristics.
Ford I, Blauw GJ, Murphy MB, Shepherd J, Cobbe SM, Bollen EL, Buckley BM, Jukema JW, Hyland M, Gaw A, Lagaay AM, Perry IJ, Macfarlane P, Norrie J, Meinders AE, Sweeney BJ, Packard CJ, Westendorp RG, Twomey C, Stott DJ; The PROSPER Study Group. Ford I, et al. Among authors: jukema jw. Curr Control Trials Cardiovasc Med. 2002 May 20;3(1):8. doi: 10.1186/1468-6708-3-8. Curr Control Trials Cardiovasc Med. 2002. PMID: 12097148 Free PMC article.
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.
Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG; PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Shepherd J, et al. Among authors: jukema jw. Lancet. 2002 Nov 23;360(9346):1623-30. doi: 10.1016/s0140-6736(02)11600-x. Lancet. 2002. PMID: 12457784 Clinical Trial.
Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events.
Boekholdt SM, Agema WR, Peters RJ, Zwinderman AH, van der Wall EE, Reitsma PH, Kastelein JJ, Jukema JW; REgression GRowth Evaluation Statin Study Group. Boekholdt SM, et al. Among authors: jukema jw. Circulation. 2003 May 20;107(19):2416-21. doi: 10.1161/01.CIR.0000068311.40161.28. Epub 2003 May 12. Circulation. 2003. PMID: 12742999 Clinical Trial.
The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the cholesterol and recurrent events study: no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome: a prospective analysis of the CETP TaqIB polymorphism on cardiovascular outcome and interaction with cholesterol-lowering therapy.
de Grooth GJ, Zerba KE, Huang SP, Tsuchihashi Z, Kirchgessner T, Belder R, Vishnupad P, Hu B, Klerkx AH, Zwinderman AH, Jukema JW, Sacks FM, Kastelein JJ, Kuivenhoven JA. de Grooth GJ, et al. Among authors: jukema jw. J Am Coll Cardiol. 2004 Mar 3;43(5):854-7. doi: 10.1016/j.jacc.2003.08.056. J Am Coll Cardiol. 2004. PMID: 14998629 Free article.
Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk population study.
Boekholdt SM, Kuivenhoven JA, Wareham NJ, Peters RJ, Jukema JW, Luben R, Bingham SA, Day NE, Kastelein JJ, Khaw KT. Boekholdt SM, et al. Among authors: jukema jw. Circulation. 2004 Sep 14;110(11):1418-23. doi: 10.1161/01.CIR.0000141730.65972.95. Epub 2004 Aug 30. Circulation. 2004. PMID: 15337694
1,096 results